In mammalian cells, terminal differentiation is mutually exclusive with proliferation. However, resistance to differentiation-inducing therapy requires alternative strategies to control poorly responsive tumors. We now show that retroviral transfer of the antisense cyclin D1 gene to differentiationrefractory K1735 melanoma leads to loss of in vivo tumorigenicity, shortened replicative ability, induction of the tumor suppressor p53 protein and of the cdk-inhibitor p21WAF1, increased b-galactosidase pH 6.0 activity, and elevation in the ratio of superoxide dismutases to peroxidases, all properties associated with replicative senescence. However, pigmentation and tyrosinase expression, characteristic of differentiated melanocytic cells or apoptosisassociated PARP cleavage, were not increased by antisense cyclin D1 transduction. Our data suggests that targetting cyclin D1 inhibition suppresses melanoma tumorigenicity by promoting a cytostatic differentiation-independent pathway, mediated by activation of p53 and anti-oxidant functions.
Introduction
Normal human diploid fibroblasts can undergo replicative senescence after a finite number of doublings in culture concurrently with increased expression of a senescenceassociated b-galactosidase active at pH 6.0, with no comparable behavior in malignant cells, which are immortal under similar conditions. 1 Both the tumor suppressor p53 protein 2 ± 4 and the cyclin-dependant kinase inhibitor p21WAF1 are also important in senescence, 5 and cell cycle progression. 6 ± 8 In particular, p53 has been recently implicated in the transcriptional induction of redox-related genes involved in the processing of reactive oxygen species. 9 Reactive oxygen species are also known to play a role in regulating senescence 10 and malignancy. 11 Increased expression of anti oxidant enzymes like Cu/Zn Superoxide Dismutase (Cu/Zn SOD), 12 and Manganese superoxide dismutase (Mn SOD), 13 has been associated with suppression of tumorigenicity and metastatic ability. Senescence is also partly regulated by p16INK 4A, a cyclin-dependent kinase inhibitor of the cyclin D/cdk4/Rb pathway, which drives the G1 to S-phase progression of the cell cycle. 14, 15 However, the p16-cyclin D-cdk 4-pRB pathway is frequently altered 16 or inactivated 17 in most melanoma tumors. Nevertheless, downregulation of this pathway concurrently with a decrease in cyclin D1 is detected in B16 melanoma undergoing terminal differentiation and replicative senescence. 18, 19 The latter results suggest a mutually exclusive interplay between differentiation and proliferation, 20 in which malignancy is usually associated with cyclin D1 overexpression. 19 , 21 Here we show that targeted decrease of cyclin D1 expression by introduction of an antisense cyclin D1 sequence 22 into undifferentiated K1735 melanoma cells, 23 induces loss of in vivo tumorigenicity, reversal of immortalization, increase in senescence-associated b-galactosidase 1 and induction of p53 2 ± 4 and p21WAF1 5 like that seen in senescent diploid cells. We also demonstrate that targeted decrease of cyclin D1 by an antisense to cyclin D1 also leads to an elevation of Superoxide Dismutases relative to Peroxidases, like that seen in cellular senescence. 24 However, reversal of tumorigenicity by an antisense cyclin D1 cDNA, which activates the p53-p21WAF1 pathway and restores anti-oxidant activities, occurs without apparent cell death or concomitant increase in pigmentation or tyrosinase expression in K1735 melanoma cells, which are properties characteristic of melanocytic cell differentiation. 18 Our findings imply that in vivo and in vitro growth suppression of tumors refractory to differentiation 25 can occur independently of increased differentiation 20 and without cell death by induction of tumor growth retardation 26 mediated by an increase in p53 and superoxide dismutases.
Results
Loss of in vitro proliferative capacity and in vivo tumorigenicity by transduction of an antisense to cyclin D1 in differentiation-refractory K1735 melanoma suppression of growth and tumorigenicity concurrent with down-regulation of cyclin D1 by L-tyrosine induction of terminal differentiation in partly pigmented B16 melanoma, 19 we investigated whether a similar response occurred after antisense cyclin D1 gene transfer 22 in K1735 melanoma refractory to differentiation. Attempts to obtain surviving cells after introduction of this plasmid into pigmented B16 melanoma completely failed, since cells became terminally differentiated 18, 19 and could not be subcultured (not shown). In contrast to B16 melanoma which responded to 1 mM Ltyrosine by undergoing terminal growth arrest and increasing pigmentation, K1735 cells which are unpigmented 23 failed to show a comparable response after transduction with antisense to cyclin D1 or with control vector (Figure 1 ). Neo resistant cells K1735 surviving cells obtained after retroviral transduction with control or antisense cyclin D1 retroviral pMV7neo vector, were pooled to examine the effects of antisense cyclin D1 on these melanoma tumors unresponsive to pigmentation-inducing agents. By comparative immune precipitation with antibody to cdk4 and replica Western blotting vs cdk4 or p16, K1735 cells behaved like most melanoma lines in which p16 is non-functional, 17 by failing to show p16 protein binding to cdk4, 17 in contrast to that detected under comparable conditions with similar levels of cdk4 protein (not shown) in normal Melan A melanocytes. 19 After retroviral transduction of the antisense to cyclin D1, K1735 cultures yielded slow-growing neomycin-resistant cells, with a doubling time of approximately 65 h within the first 4 ± 6 in vitro passages compared to a doubling time of only 24 h of the same cells transduced with the same vector lacking the antisense cyclin D1 gene (Table 1 ). In spite of the common lack of pigmentation in response to tyrosine, K1735 cells harboring the empty neo vector grew in dense multilayers, showing a typical malignant morphology. In contrast, multilayers were not seen in K1735 cells harboring the antisense to cyclin D1, which showed lower cell density, increased cell-cell interaction, and greater flattening on their substratum (Figure 1 ). This different morphology of cells transduced with anticyclin D1 was paralleled by a much slower replicative potential following clonal expansion, even when cultures were provided with 5 ± 20% serum, including EGF or FGF supplements in the 2 ± 50 ng/ml range. 18 In parallel with the morphological changes seen in Figure 1 , detection of the senescence-associated b-galactosidase activity at pH 6.0 13 was also increased from 4 to around 37% in cells transduced with antisense to cyclin D1 (Table 1) . Also, in vivo tumorigenic ability was completely suppressed in the latter cells, in contrast with no comparable suppression in control cells transfected with the empty plasmid ( Table 1) .
Antisense to cyclin D1 promotes binding of p27kip1 to Cyclin A and decreases Rb phosphorylation
We compared the effect of introducing the antisense to cyclin D1 on the expression of several cell cycle regulatory proteins by immune blotting with well characterized specific antibodies. Cell lysates were prepared from control cells transduced with the neo resistance pMV7 plasmid, and from cells transduced with the pMV7D1AS plasmid in which the antisense to cyclin D1 was inserted into the vector. 22 These experiments revealed that cyclin D1 was preferentially decreased in cells transduced with antisense to cyclin D1, with no comparable effects on cyclin D3 or cdk4. This was associated with an increase in the slow-migrating, hypophosphorylated form of the Retinoblastoma Rb protein, in contrast to the preferential expression of upper hyperphosphorylated Rb in control cells (Figure 2) . Similar results were recently reported for colon cancer cells also transduced with antisense to cyclin D1. 22 Since p27 KIP1 interacts with cyclin D1-cdk4 complexes, 27 we also investigated whether cells harboring the Figure 1 Lack of response to differentiation-inducers persists after antisense cyclin D1 gene transfer in K1735 melanoma. B16-BL6 melanoma which increase melanocytic-specific pigmentation after a 2 day exposure to 1 mM Ltyrosine, were used as a positive control (upper, right) to examine a comparable response in either K1735 melanoma transduced with antisense to cyclin D1 (middle), or the same cells transduced with control vector (lower) antisense to cyclin D1 differed from control cells in p27 KIP1-cyclin-cdk interactions. Immune precipitation with antibody to p27 KIP1 followed by electrophoretic analysis and immune blotting revealed cyclin D1 and cdk4 association with p27 KIP1 in control cells as reported for growing Swiss 3T3 cells. 27 In contrast complex formation between either p27 KIP1 and cyclin A or p27KIP1 and cdk2, was preferentially evidenced in cells transduced with antisense to cyclin D1 ( Figure 3 ). This resembles the increased association of cyclin A with p27KIP1 reported in anti-IgM induced grown arrest of WEHI-23 B cell lymphoma. 28 p21WAF1 mRNA and expression of p53 and p21WAF1 proteins are induced by antisense to cyclin D1 without an increased in differentiationassociated tyrosine
Since the tumor suppressor p53 2 ± 4 and the cyclin-dependent kinase inhibitor p21WAF1 5 ± 8 are also important in senescence, tumorigenesis and cell cycle progression, we also investigated whether expression of these proteins and their mRNAs differed in cells unequally expressing cyclin D1. Since Northern blots required high amounts of total RNA and cells transduced with antisense to cyclin D1 grew very slowly, we used RT ± PCR to investigate mRNA levels of p53, p21WAF1, as well as those of tyrosinase, which is an initial limiting step in melanocytic cell pigmentation, 18 for comparison with a usually constitutive gene like GAPDH. 12 These experiments revealed comparable mRNA levels of p53, tyrosinase and GAPDH in K1735 control melanoma and those harboring an antisense cyclin D1. However, the latter cells showed a selective increase in p21WAF1 mRNA compared to that of control RNA (Figure 4 , left).
We also investigated whether protein expression of p53 and p21WAF1 and tyrosinase ( Figure 4 , right) were influenced by transduction of an antisense to cyclin D1. 22 and senescenceassociated b-galactosidase pH 6.0 was assayed. 3 Cell culture assays were performed in triplicate which agreed within 7%, and animal experiments used triplicates of seven mice per assay In agreement with reports showing that senescent cells express more p53, 2, 4 we also observed increased expression of p53 protein in K1735 cells with limited replicative ability obtained by transduction of antisense to cyclin D1. This was paralleled by concomitant induction of p21WAF1 protein, whose expression is known to be activated by p53 6 ± 8 and induced in senescent cells. 5 However, increases in p53 and p21WAF1 protein by antisense cyclin D1 gene transfer, were not paralleled by increases in pigmentation-associated melanin (Table 1) or tyrosinase expression 18 which remained similar both at the mRNA and protein levels in cells transduced with control or antisense cyclin D1 gene (Figure 4 ).
Superoxide dismutases but not glutathione peroxidase or catalase are increased in cells transduced with antisense to cyclin D1
Reactive oxygen plays a major role in the aging process, 10 Mn superoxide dismutase expression is inversely correlated with metastatic ability 13 and an elevation in the ratio of Cu/Zn superoxide dismutase to glutathione peroxidase has been recently correlated with senescence. 24 Hence, we compared the expression of several anti oxidant enzymes in control tumorigenic, immortal cells and in those in which tumorigenicity and replicative ability was suppressed by introduction of antisense to cyclin D1. This also revealed an elevation in superoxide dismutases compared to that of glutathione peroxidase and catalase ( Figure 5 ), similar to that seen in senescent fibroblasts.
10,24
PARP cleavage is not increased by antisense cyclin D1 gene transfer Since K1735 melanoma transduced with antisense cyclin D1 failed to form in vivo tumors and colonies in agar, showing also a much slower proliferation in tissue culture, we investigated whether this was associated with increased PARP cleavage, which frequently correlates with apoptosis. 29 For this, we compared adherent K1735 cells transduced with either control vector or with the vector harboring the antisense cyclin D1 gene, as shown in Figure 1 . Immune blots with a PARP antibody which recognizes the intact molecule and the 85 kd fragement frequently cleaved during apoptosis, revealed a comparable amount of both species in cells transduced with antisense cyclin D1 or control vector ( Figure  6 ). As a positive indicator of apoptotic response, we used control cells analyzed 24 h after exposure to 25 J/m 2 , which showed an increase in the lower 85 kd form ( Figure 5 ). These experiments imply that the effects of antisense cyclin D1 leading to K1735 tumor suppression do not involve extensive PARP fragmentation. 
Discussion
We have now demonstrated that decreasing cyclin D1 expression by introduction of an antisense cyclin D1 gene leads to in vivo loss of tumorigenicity and to a diminished in vitro replicative ability in K1735 melanoma. These properties were paralleled by a relative increase in the non-phosphorylated tumor suppressive form of Rb, 22 and by an increased binding of the cdk inhibitor p27 KIP1 to cyclin A and cdk2, 28 properties known to be associated with growth arrest, since they decrease the ability of cells to enter S-phase. 28 Although senescent normal fibroblasts do not express cyclin A, 30 a number of tumor cells fail to down-regulate cyclin A with serum starvation 31, 32 or terminal differentiation, 33 even those transduced with antisense to cyclin D1 (Figure 3) . However, the aberrantly regulated cyclin A pathway of malignant cells 31 ± 33 can be bypassed in the latter cells by suppressing tumor growth through down-regulation of cyclin D1. Although our results are compatible with prior studies showing lung cancer cell retardation 26 or induction of growth arrest in colonic tumors by antisense to cyclin D1, 22 we are the first to show that suppression of growth and tumorigenicity by antisense cyclin D1 gene transfer occurs without reacquisition of cell-specific differentiation 18 in K1735 melanoma. 23 However, the shortened life span now observed after antisense cyclin D1 gene transfer into K1735 melanoma, resembled that obtained by L-tyrosine induction of terminal differentiation which also decreased cyclin D1 without affecting cyclin A in differentiation-proficient B16 melanoma. 19 Moreover, our data shows that antisense cyclin D1 increases expression of senescence-associated b-galactosidase 1,3 concurrently with induction of p53, 2,4 and p21WAF1 5 in K1735 melanoma cells, independently of inducing tyrosinase-associated differentiated properties. 18 RT ± PCR showed induction of p21WAF1mRNA without increase in p53 mRNA in K1735 transduced with antisense cyclin D1, in agreement with data comparing senescing with young fibroblasts. 2 However, p53 protein and p21WAF1 protein were both increased in K1735 transduced with antisense cyclin D1, results similar to those reported for normal fibroblasts induce to senesce by oncogenic H-Ras V-12. 3 These results suggest that the tumor suppressive effects of introducing an antisense cyclin D1 gene into K1735 (Table 1) are partly mediated by activation of the p53/p21WAF1 pathway. 6 Another novel change detected in K1735 melanoma cells transduced with antisense to cyclin D1 was an increase in anti-oxidant enzymes concurrent with suppression of immortalization and tumorigenicity. This was reflected by an increased expression of Cu/Zn superoxide dismutase 12 and Mn superoxide dismutases 13 but not of glutathione peroxidase or catalase. Overexpression of superoxide dismutases has been shown to suppress the melanoma malignant phenotype. 13 Also, a similar elevation in the ratio of dismutases to peroxidases like that seen in cells transduced with antisense to cyclin D1, has been correlated with senescence features in human cells. 24 To our knowledge, this is the first study linking antisensemediated suppression of cyclin D1 expression 22 with concomittant increases in specific anti-oxidant enzymes and activation of the p53/p21 pathway without hypoxia 34 or genotoxic damage. 6 ± 8 It was recently demonstrated in melanomas that accumulation of p53 in S-phase during hypoxia was not related to hypoxia-induced apoptosis. 34 This is compatible with the present data showing lack of PARP cleavage with p53 overexpression in cells transduced with anti cyclin D1, which also revealed induction of superoxide dismutases. The latter is also compatible with reports that p53 not only induces genes like p21WAF1 but also activates genes implicated in anti-oxidant functions. 9 Increase in anti-oxidant enzymes like Cu/Zn superoxide dismutases like that seen in anti-cyclin D1 transduced melanoma has also been recently described in aged cells of a transgenic model for Alzheimer's disease. 35 Recent results have demonstrated that virtually 100% of melanoma cell lines have a non-functional p16INKa gene 36 extending prior findings in cultured melanoma cells and primary tumors. 16, 17 Such reports are in agreement with our own functional observations (not shown) that K1735 melanoma resemble most melanoma lines by failing to show functional p16 protein binding to cdk4, 17, 36 in contrast to that seen under comparable conditions in normal melanocytes (not shown). Nevertheless, our data suggest an alternative modulation of the p16 INK4A-cyclin D1-cdk 4-Rb pathway via antisense cyclin D1 as a cytostatic option to slow the proliferation and suppress the in vivo tumorigenicity of K1735 melanoma. The effect of antisense cyclin D1 to induce growth suppression and acquisition of properties partly associated with a senescent phenotype in differentiation-refractory K1735 melanoma, extends our prior findings demonstrating acquisition of a senescence-like growth arrest in B16 melanoma, when cyclin D1 is alternatively down-regulated after induction of terminal differentiation in B16 melanoma. 18, 19 Our data showing inhibition of replicative ability (Table 1) with loss of cyclin D1, represents a cytostatic alternative to learn about negative control mechanisms different from terminal differentiation or apoptosis. Lack of cell death in anticyclin D1 transduced K1735 cells was assessed by their ability to attach and remain flattened on their substrate for weeks (Figure 1) , by their ability to exclude trypan blue (not shown) and by their Differentiation-independent cytostatic arrest M Rieber and M Strasberg Rieber lack of apoptosis-associated PARP cleavage 29 ( Figure 6 ). Whereas apoptosis may involve activation of deathinducing genes, 29 antisense cyclin D1 appears to decrease proliferation and supress tumorigenicity partly by activating expression of the p53 protein without any additional stress. Induction of p53 in K1735 melanoma via down-regulation of cyclin D1 is novel, since the p53 protein is unstable in proliferating cells, 3, 34 and known to be stabilized by genotoxic stress, 6 ± 8 hypoxia 34 or by oncogenic ras induction of senescence in normal fibroblasts. 3 Hence, joint induction of the p53 protein and the cdkinhibitor p21WAF1, with concomitant induction of superoxide dismutases, also known to suppress malignancy 9 ± 13 are involved in the mechanism of growth arrest without differentiation or apoptosis in anticyclin D1 transduced cells. Further studies should be carried out to define the reason why cyclin D1 decreases are common for growth inhibition in differentiation-proficient B16 melanoma 37 and differentiation-refractory K1735 melanoma, 23 since both are known to harbor wt p53 inducible by stress. 23, 37 In tumors like melanomas, in which the cyclin D1/Rb control pathway is impaired because of a frequently inactivated p16 INK4A tumor suppressor gene, 17, 36 targeted down-regulation of cyclin D1 may compensate for a defective p16 INK4A gene 34 by alternative activation of the p53/p21WAF1 pathway and basal superinduction of superoxide dismutases. In support of our findings of a inverse relationship between cyclin D1 and p53 in K1735 cells, we recently demonstrated that UV concomitantly induced p53 and Cu/Zn superoxide dismutase with a reciprocal decrease in cyclin D1 in other melanomas. 12.37 The latter findings imply a reciprocal relationship between high p53 and low cyclin D1 in melanomas exposed to UV irradition, although the present studies suggest that cyclin D1 down-regulation favors overexpression of basal p53 protein, even without genotoxic stress. 6 ± 8 Recently, cyclin D1 overexpression was demonstrated in 65% of uveal melanoma biopsies, emphasizing the relevance of cyclin D1 in this tumor type. 38 This further suggests that antagonizing expression of cyclin D1, 19, 21 may be important to control or revert a number of changes associated with multi-stage melanoma progression ( Table 1) .
Considering that the p16-cyclin D.cdk4 pathway is usually non-functional in melanoma tumors, 16, 34 and the lower cyclin D1 protein expression in non-proliferating melanocytes than in melanomas, 19, 38 our data also suggests that use of melanocyte-specific promoters 39 preceding an antisense cyclin D1 sequence could provide the basis for a targeted retroviral vector potentially helpful against melanomas refractory to differentiation 25 and other traditional therapies.
Materials and Methods

Cells
K1735 unpigmented melanoma were isolated originally and passaged in C3H mice. 23 Intravenous injection of 50 000 cells per mice, yielded 20 ± 30 lung colonies, using cells transfected with control pMV7 plasmid, vs no lung colonies in the same cells transfected with antisense to cyclin D1 pMV7 D1AS in pMV7 plasmid. 22 Also, foot-pad s.c. injection of 75 000 cells transfected with control plasmid produced a detectable tumor without 5 ± 6 weeks, with no comparable tumor evident by 14 weeks in cells transduced with the antisense to cyclin D1 (Table 1) .
Retroviral transduction
The pMV7 control or antisense to cyclin D1 pMV7 D1AS were cultured in E. coli cells, and the purified plasmid DNA samples (10 mg) were transfected with lipofectin (10 mg) (GIBCO-BRL) into GPAM 12 cells to generate defective retroviral particles. 22 The viral supernatants were harvested and used to transduce either pigmentation-inducible B16 melanoma 18 or unpigmented K1735 melanoma. 23 Only the latter yielded surviving neomycin-resistant cells selectable with G418 geneticin (0.6 mg/ml), which were subsequently demonstrated to have the neo r gene by Southern blot (not shown). Down-regulation of cyclin D1 in these cells was confirmed by immune blotting. Experiments to be described with cells transduced with antisense to cyclin D1 plasmid of control vector, were carried out within 2 ± 3 passages of selection of neo r cultures, after primary clonal expansion.
Reverse transcription ± PCR
DNAse-treated total RNA (2 mg) from control or antisense-transduced cells was reverse-transcribed with SuperScript II reverse transcriptase with oligo dT for 60 min at 428C. One tenth of the corresponding cDNA was used for specific hot-start PCR (958C for 5 min), and adding cDNA for 30 cycles at 948C for 45 s, 588C for 45 s and 728C for 2 min, followed by 7 min at 728C. GADPH and p53 primers used for PCR were from Clontech (Palo Alto, CA, USA). For p21WAF1, forward primers covered from nucleotide 80 ± 108 and the reverse primer from nucleotide 584 ± 560. These primers and those for the first exon of the tyrosinase gene used as control for melanocytic cells 33 were obtained from Genosys (Houston, Texas, USA).
Immune blotting
Extracts were prepared and immune blotted as described elsewhere. 32 For Western blotting, detection of p53 was carried out with either antibody PAB 421 and PAB 240 from Oncogene Science. We also used C-19 antibody to the C terminal domain of p21 WAF1 (SC-397), antibody to p27 KIP 1 (SC-528), antibody to Rb (SC-102), antibody to cyclin D3 (SC-182), and antibody to PARP (SC-7150) were obtained from Santa Cruz Biotechnology, Santa Cruz, California. We thank Dr. Larry Oberley, University of Iowa, for antibodies to either Mn or Cu/Zn Superoxide dismutases, Dr. M Pagano, (NY University, USA) for antibodies to cyclin D1, cdk2 and cdk4, Dr. Greg Hannon (Cold Spring Harbor Laboratory, NY, USA) for antibody to p16, and Dr. Vincent J Hearing, (National Institutes of Health, Bethesda, MD, USA) for antibody to tyrosinase. After reaction with primary antibodies, blots were reacted with the corresponding species-specific secondary antibodies, followed by detection with ECL chemiluminescence (Amersham).
Senescence-associated b-galactosidase
This was assayed after washing cells in PBD, fixation in 0.5% glutaraldehyde in PBS pH 7.2 washing in PBS with 1 mM MgCl 2 , staining with 1 mg/ml X-gal (Gibco-BRL), 0.12 mM K 4 Fe(CN) 6 , K 4 Fe(CN) 6 , 1 mM Mgcl 2 in PBS pH 6.0 (3). Staining was allowed to proceed for 16 h at 378C in the absence of CO 2 , to maintain pH 6.0 during b-gal staining.
